Information Provided By:
Fly News Breaks for April 10, 2015
SGEN
Apr 10, 2015 | 07:21 EDT
After meeting with an expert, RBC Capital reports that he believes that off-label use of Seattle Genetics' Adcetris is increasing across a variety of indications. He believes that Adcetris is approvable and has a better chance of becoming a front-line treatment than competing drugs. The firm keeps a $50 price target and Outperform rating on the shares.
News For SGEN From the Last 2 Days
There are no results for your query SGEN